Adherex Technologies (FENC) Stock Price, News & Analysis

Company Overview

Adherex Technologies was a biotechnology company that focused on developing therapies for cancer and other serious medical conditions. The company later changed its name to Fennec Pharmaceuticals, while continuing to trade under the symbol FENC.

Fennec’s principal product is PEDMARK, a formulation of sodium thiosulfate designed to reduce the risk of cisplatin-induced ototoxicity, or hearing loss, in pediatric patients receiving chemotherapy. PEDMARK is administered in conjunction with cisplatin and is intended to address a significant treatment-related complication in children with cancer.

The company’s activities have centered on the development, regulatory approval and commercialization of PEDMARK for pediatric oncology care. Fennec Pharmaceuticals is based in the United States and serves the pediatric cancer treatment market through commercial and healthcare relationships in North America. Adherex Technologies’ earlier development programs provided the foundation for the company’s transition into Fennec Pharmaceuticals.

Key Stats

• Today's Range: $10.57 to $10.85
• 50-Day Range: $9.57 to $12.78
• 52-Week Range: $5.65 to $13.25
• Volume: 52,951 shs
• Average Volume: 205,054 shs
• Market Capitalization: $378.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.00
• Consensus Rating: Moderate Buy

Adherex Technologies Stock Analysis - MarketRank™

Adherex Technologies scored higher than 80% of companies evaluated by MarketBeat, and ranked 107th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Adherex Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Adherex Technologies has a consensus price target of $17.00, representing about 58.8% upside from its current price of $10.71.

Amount of Analyst Coverage

Adherex Technologies has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 246.43%

Earnings Growth

Earnings for Adherex Technologies are expected to grow by 246.43% in the coming year, from $0.28 to $0.97 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Adherex Technologies is -82.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Adherex Technologies is -82.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Adherex Technologies has a P/B Ratio of 10.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.74% of the float of Adherex Technologies has been sold short.

Short Interest Ratio / Days to Cover

Adherex Technologies has a short interest ratio ("days to cover") of 2.11, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Adherex Technologies has recently increased by 4.68%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Adherex Technologies does not currently pay a dividend.

Dividend Growth

Adherex Technologies does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Adherex Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,029,660.00 in company stock.

Percentage Held by Insiders

10.73% of the stock of Adherex Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

55.51% of the stock of Adherex Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/09/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:FENC
• CIK: 1211583
• Web: www.fennecpharma.com
• Phone: 919-636-4530
• Fax: 919-890-0490
• Employees: 35
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Adherex Technologies: $17.00
• High Price Target: $18.00
• Low Price Target: $16.00
• Potential Upside/Downside: +58.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 38.43
• P/E Growth: N/A
• Net Income: -$9.74 million
• Net Margins: -6.09%
• Pretax Margin: -5.24%
• Return on Equity: -5.71%
• Return on Assets: -2.37%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.85
• Quick Ratio: 5.66

Sales & Book Value

• Annual Sales: $59.22 million
• Price / Sales: 6.38
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.04 per share
• Price / Book: 10.35

Miscellaneous

• Outstanding Shares: 35,138,000
• Free Float: 31,368,000
• Market Cap: $378.12 million
• Optionable: Optionable
• Beta: 1.23